Scorpius Holdings, Inc.

SCPX

Capitalización de mercado USD 394 k

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Scorpius Holdings, Inc. (the “Company”) — ticker symbol SCPX — from NYSE American. Trading in the Company's common stock will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide.

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has engaged Alliance Global Partners (“A.G.P.”) to assist in exploring strategic alternatives for the Company. This engagement is part of the Company's ongoing efforts to maximize shareholder value and evaluate a range of potential strategic opportunities. Scorpius' leadership remains committed to leveraging its scientific and technical expertise to enhance its position in the biomanufacturing sector while considering various avenues to drive long-term growth.

Partnership highlights Scorpius' expertise in supporting innovative therapeutic programs Partnership highlights Scorpius' expertise in supporting innovative therapeutic programs

DURHAM, N.C., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company's planned 1-for-20 reverse stock split (the “Reverse Stock Split”) of its common stock (the “Common Stock”) that was announced yesterday, will not be effectuated.

DURHAM, N.C., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”), to increase the selling price of the Company's Common Stock in order to maintain compliance with the requirements and policies of the NYSE American.

New business unit offers services for promising biotech companies through combined fee-for-service and equity-based model, fostering partnerships that align with BIOSECURE Act goals to onshore and strengthen U.S.-based biosecurity and production capacity New business unit offers services for promising biotech companies through combined fee-for-service and equity-based model, fostering partnerships that align with BIOSECURE Act goals to onshore and strengthen U.S.-based biosecurity and production capacity

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024.

DURHAM, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced a partnership with Celltheon Corporation to provide cell line development services to clients using Celltheon's proprietary GOLDILOCKS™ transposase-based platform.

DURHAM, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annually.

Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases